RefinedScience

RefinedScience

Data-driven precision medicine for trials

Overview

RefinedScience builds a data platform that combines clinical and biological data to support precision drug development and clinical trial optimization using AI and machine learning. It curates high-fidelity data and runs computational analyses to identify which patients are most likely to respond and how to design trials, delivering data-driven insights as a service to pharmaceutical companies and healthcare institutions. Unlike providers that only offer datasets, RefinedScience integrates rich data with advanced analytics to give actionable, patient-focused guidance. Its goal is to improve patient outcomes and shorten drug development timelines by increasing trial success and speeding up discovery to approval.

About RefinedScience

Simplify's Rating
Why RefinedScience is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

Aurora, Colorado

Founded

2019

Get referred to RefinedScience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 Verily partnership expands distribution into a major healthcare AI ecosystem.
  • The AML dataset showed 95%+ accuracy and 30x faster extraction, strengthening commercialization.
  • Permanent Bioscience 3 headquarters in 2024 signals long-term commitment and hiring capacity.

What critics are saying

  • RefinedScience’s 18-person team cannot support enterprise sales, curation, and platform delivery.
  • Its moat depends on UCHealth and CU Anschutz access; partner drift kills supply.
  • If Verily or academia internalizes this workflow by 2027, RefinedScience becomes redundant.

What makes RefinedScience unique

  • RefinedScience’s October 2025 Verily collaboration validates its AI-ready clinical data pipeline.
  • Its UCHealth and CU Anschutz joint venture gives proprietary access to multiomic patient data.
  • The Verily Exchange now hosts its AML dataset, proving marketable data-product traction.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Holidays

Paid Sick Leave

401(k) Retirement Plan

Company News

Business Wire
Nov 22nd, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Recently Posted Jobs

Sign up to get curated job recommendations

RefinedScience is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →